AR120667A1 - MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE - Google Patents
MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USEInfo
- Publication number
- AR120667A1 AR120667A1 ARP200103371A ARP200103371A AR120667A1 AR 120667 A1 AR120667 A1 AR 120667A1 AR P200103371 A ARP200103371 A AR P200103371A AR P200103371 A ARP200103371 A AR P200103371A AR 120667 A1 AR120667 A1 AR 120667A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- muscarinic receptor
- antagonists
- formula
- pharmaceutically acceptable
- Prior art date
Links
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 title abstract 3
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan en la presente compuestos de la fórmula (1) o una sal del mismo farmacéuticamente aceptable. También se proporcionan métodos para tratar enfermedades, trastornos o síntoma antagonizando receptores muscarínicos, incluyendo específicamente antagonizar receptor muscarínico 4 (M4). Reivindicación 1: Un compuesto que tiene la estructura de la fórmula (1) o una sal del mismo farmacéuticamente aceptable.Compounds of formula (1) or a pharmaceutically acceptable salt thereof are provided herein. Also provided are methods of treating diseases, disorders, or symptoms by antagonizing muscarinic receptors, including specifically antagonizing muscarinic receptor 4 (M4). Claim 1: A compound having the structure of formula (1) or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944647P | 2019-12-06 | 2019-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120667A1 true AR120667A1 (en) | 2022-03-09 |
Family
ID=80996988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200103371A AR120667A1 (en) | 2019-12-06 | 2020-12-03 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR120667A1 (en) |
-
2020
- 2020-12-03 AR ARP200103371A patent/AR120667A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021008817A2 (en) | Thrβ receptor agonist compound and method of preparation and use thereof | |
| CO2018004800A2 (en) | Muscarinic 4 receptor antagonists and methods of use. | |
| CO2021000078A2 (en) | Derivatives of 3- (5-hydroxy-1-oxoisoindolin-2-yl) piperidine-2,6-dione and their use in the treatment of ikaros family zinc finger protein-dependent 2 disorders (ikzf2) | |
| MX2023009611A (en) | NEUROACTIVE STEROIDS, AND THEIR METHOD OF USE. | |
| MX2022005886A (en) | GLP-1 RECEPTOR AGONIST AND USE OF IT. | |
| MX2021013075A (en) | OXYSTEROLS AND METHODS OF USE THEREOF. | |
| CR9910A (en) | HISTAMINE RECEIVER 3 ANTAGONISTS | |
| GT200900283A (en) | "COMBINATION THERAPY WITH A COMPOUND ACTING AS AN ADP PLAQUETARY RECEPTOR INHIBITOR". | |
| EA202092253A1 (en) | SUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS PRMT5 INHIBITORS | |
| ECSP034809A (en) | CICLOBUTENO-1,2-DIONAS 3,4-DISUSTITUTED AS LIGANDS OF THE CXC CHEMOCINE RECEIVER | |
| BR112022000598A2 (en) | Urea compound for lpa1 receptor antagonization | |
| AR117814A1 (en) | FXR MODULATOR COMPOUNDS (NR1H4) | |
| CO2018009561A2 (en) | Methods for treating depression with orexin-2 receptor antagonists | |
| BRPI0411699A (en) | compounds for use as a therapeutically active substance; method for the treatment and / or prophylaxis of diseases that are associated with cb1 receptor modulation and use of these compounds | |
| ECSP22092977A (en) | CRF1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | |
| BR122018070508B8 (en) | triazole-substituted arylamide derivatives and their use | |
| ECSP067123A (en) | NK1 ANTAGONISTS | |
| CA3156666A1 (en) | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | |
| BR112021011325A2 (en) | Rapamycin derivatives | |
| MX2021012248A (en) | POLYMORPHS OF VORUCICLIB AND METHODS OF PREPARATION AND USE THEREOF. | |
| CY1117826T1 (en) | MORFINANIS UNITS | |
| EA202190398A1 (en) | CONDENSED RING DERIVATIVE USED AS FGFR4 INHIBITOR | |
| CL2022000893A1 (en) | 2-Azaspiro[3,4]octane derivatives as m4 agonists | |
| CO2019013254A2 (en) | 5,6-fused bicyclic compounds and compositions for the treatment of parasitic diseases | |
| AR107937A1 (en) | CINOLIN-4-AMINA COMPOUNDS AND ITS USE IN CANCER TREATMENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |